Safety, pharmacokinetics, and immunological activities of multiple intravenous or subcutaneous doses of an anti-HIV monoclonal antibody, VRC01, administered to HIV-uninfected adults: Results of a phase 1 randomized trial
Kenneth H. Mayer(Miriam Hospital), Derrick Goodman(Duke Medical Center), David C. Montefiori(Duke University), Hong‐Van Tieu(New York Blood Center), Nicole Grunenberg(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Yunda Huang(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Mary Allen(National Institutes of Health), Benigno Rodríguez(Case Western Reserve University), Barney S. Graham(National Institutes of Health), Georgia D. Tomaras(National Institutes of Health), Abby Isaacs(Fred Hutch Cancer Center), Guido Ferrari(Duke University), Lawrence Corey(Fred Hutch Cancer Center), Ryan L. Jensen(Fred Hutch Cancer Center), Ian Frank(Norwegian Womens Public Health Association), Robert T. Bailer(National Institutes of Health), John R. Mascola(National Institute of Allergy and Infectious Diseases), Julie E. Ledgerwood(Vaccine Research Institute of San Diego), Magdalena E. Sobieszczyk(Columbia University Irving Medical Center), Lindsey R. Baden(Brigham and Women's Hospital), Aaron Deal(Duke Medical Center), Kelly E. Seaton(International Vaccine Institute), John Hural(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa)
Cited by 132
Related Papers
Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus
|Cell|2020|4.5k
Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19
|New England Journal of Medicine|2021|2.6k
Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host
|New England Journal of Medicine|2020|1.4k